Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Rhea-AI Summary

Ascentage Pharma (NASDAQ:AAPG; HKEX:6855) will present 17 clinical advances at the 31st European Hematology Association (EHA2026) Congress in Stockholm from June 11–14, 2026, including 8 posters.

Data cover ongoing studies of Olverembatinib (HQP1351) and Lisaftoclax (APG-2575), both approved in China but not yet FDA-approved in the US.

News Market Reaction – AAPG

+1.04%

+1.04% Session close to close

In the May 13 session, AAPG gained 1.04%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights expanded clinical visibility for Ascentage’s core hematology assets, wi...

Analysis

This announcement highlights expanded clinical visibility for Ascentage’s core hematology assets, with 17 advances and 8 posters accepted at EHA2026, including registrational Phase 3 and pivotal Phase 2 studies. It underscores the strategic focus on olverembatinib and lisaftoclax across CML, Ph+ ALL and CLL/SLL, while U.S. approvals have not yet been secured. Investors may track upcoming data readouts, regulatory interactions and any updates to the broader development or commercialization plans following these presentations.

Key Figures

Clinical advances: 17 advances Poster presentations: 8 posters EHA Congress edition: 31st Congress +5 more

8 metrics

Clinical advances 17 advances Core assets featured at EHA2026

Poster presentations 8 posters EHA2026 Congress presentations

EHA Congress edition 31st Congress European Hematology Association 2026 meeting

EHA2026 dates June 11–14, 2026 Congress in Stockholm, Sweden

Presentation window 18:45–19:45 CEST Multiple posters on June 13, 2026

Phase designation Phase 3 POLARIS-1 global registrational study

Phase designation Phase 2 Lisaftoclax pivotal CLL/SLL study

Phase designation Phase 1B Olverembatinib + Lisaftoclax pediatric R/R Ph+ ALL study

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Conference abstracts	Positive	-0.2%	ASCO 2026 clinical abstracts including three rapid oral presentations and posters.
Apr 19	Preclinical data	Positive	-3.8%	AACR 2026 preclinical posters on combination strategies for key pipeline assets.
Mar 25	Full-year earnings	Negative	-4.8%	2025 results with US$82.1M revenue, US$177.7M loss and higher R&D spending.
Mar 17	Preclinical data	Positive	-1.4%	AACR 2026 preclinical posters across multiple tumor models for three candidates.
Mar 11	Earnings date	Neutral	-1.1%	Announcement of timing and webcast details for 2025 financial results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows AAPG often trading lower after both scientific conference announcements and earnings-related news, even when updates highlight clinical progress.

Recent Company History

Over the past few months, Ascentage Pharma has repeatedly highlighted clinical and corporate milestones, including ASCO 2026 abstracts on olverembatinib, lisaftoclax, and alrizomadlin, AACR 2026 preclinical combination data, and full-year 2025 financials with revenue of US$82.1M and a loss of US$177.7M. Despite these updates, shares generally moved lower in the following sessions, suggesting a pattern of cautious market reception to both scientific and financial disclosures ahead of today’s EHA2026 announcement.

Key Terms

bcr-abl, bcl-2, chronic myeloid leukemia, cp-cml, +4 more

8 terms

bcr-abl medical

"China’s first approved third-generation BCR-ABL inhibitor"

BCR-ABL is an abnormal gene and the protein it makes, formed when two separate genes join together in certain blood cancers; the protein acts like a stuck “on” switch that tells cells to grow uncontrollably. Investors care because BCR-ABL is a clear diagnostic marker and a proven drug target—tests that measure it guide treatment decisions and drugs that block its activity can drive sales, regulatory milestones, and clinical trial outcomes.

bcl-2 medical

"the first approved China-developed Bcl-2 selective inhibitor"

BCL-2 is a protein that helps cells avoid programmed death, acting like a brake that keeps damaged or old cells alive instead of triggering the cell’s built-in self-destruct sequence. For investors, BCL-2 matters because drugs that block or modulate it can shrink certain cancers or change treatment outcomes, which can affect a biotech company’s clinical prospects, regulatory chances, and commercial value much like a key component determining the success of a product line.

chronic myeloid leukemia medical

"CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)"

A cancer of the blood-forming cells in the bone marrow that causes too many abnormal white blood cells to be produced because of a specific genetic change; left untreated it can disrupt normal blood function and the immune system. Investors watch it because the disease has clear biological targets and well-defined treatment pathways, so advances, clinical trial results, regulatory approvals, or pricing shifts for therapies can quickly change the commercial outlook for drug makers — like a new, precision brake applied to an over-revving engine.

cp-cml medical

"CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)"

cp-cml stands for chronic phase chronic myeloid leukemia, the early and more stable stage of a blood cancer in which abnormal cells grow slowly and symptoms are often milder. It matters to investors because treatments that control or delay progression in this phase can become long-term, high-value products with predictable patient populations and regulatory pathways; think of it like treating a smoldering fire to prevent it becoming a wildfire, which affects market size and revenue predictability.

cll/sll medical

"CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)"

A blood cancer that arises when a type of white blood cell (B lymphocyte) grows out of control; when it mainly affects the bloodstream and bone marrow it’s called CLL, and when it presents mainly as swollen lymph nodes it’s called SLL—clinically they are the same disease. Think of the body’s security guards multiplying and malfunctioning instead of protecting you. Investors care because the disease drives demand for therapies, clinical trial results and regulatory approvals directly affect drug makers’ revenue, valuation and partnership or acquisition activity.

ph+ all medical

"NEWLY DIAGNOSED PH+ ALL"

Ph+ ALL is a form of acute lymphoblastic leukemia characterized by a specific genetic abnormality known as the Philadelphia chromosome, which acts like a cancer-driving fingerprint in affected blood cells. It matters to investors because this subtype often responds to targeted drugs that block the abnormal gene’s activity, creating clear development paths and commercial opportunities for therapies; think of it as a disease with a identifiable target that can make new treatments faster to develop and more valuable if effective.

relapsed/refractory medical

"PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL)"

Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.

phase 3 study medical

"A GLOBAL REGISTRATIONAL PHASE 3 STUDY"

A phase 3 study is the large-scale clinical trial that tests whether a new drug or medical treatment actually works and is safe in a broad group of patients, typically after earlier smaller tests. Investors watch these studies like a final dress rehearsal because their successful completion is often required for regulatory approval and market access; positive or negative results can sharply change a company’s future sales prospects and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for cancers and other diseases, announced today that 17 clinical advances of its core assets will be featured at the 31^st Congress of the European Hematology Association (EHA2026), including 8 poster presentations. The abstracts feature data from ongoing clinical studies encompassing Olverembatinib (HQP1351), China’s first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress will convene in Stockholm, Sweden, from June 11 to 14, 2026.

As one of the most authoritative and influential international academic meetings in hematology, the EHA Congress aggregates hematology professionals from around the world to share the latest research advances and breakthrough clinical data.

Key abstracts of accepted poster presentations include:

UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

• Abstract #: PS1733
• Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST
• First Author: Weiming Li, MD, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  

EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS

• Abstract #: PS1727
• Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST
• First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center
  

UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL

• Abstract #: PS1479
• Presentation Time: Saturday, June 13, 2026, 18:45–19:45 CEST
• First Author: Suning Chen, The First Affiliated Hospital of Soochow University
  

CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY

• Abstract #: PS1713
• Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST
• First Author: Keshu Zhou, Henan Cancer Hospital
  

SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY

• Abstract #: PS1473
• Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST
• First Author: Jingliao Zhang, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  

All abstracts (including Posters Presentation and Publication Only) are available on the EHA website.

* Olverembatinib and Lisaftoclax are currently under investigation and have not yet been approved by the FDA in the US.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:
Stella Yang
Ascentage Pharma
IR@ascentage.com 
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012

FAQ

What is Ascentage Pharma (AAPG) presenting at the EHA 2026 hematology congress?

Ascentage Pharma will present 17 clinical advances, including 8 poster presentations, at the EHA 2026 Congress. According to the company, these cover ongoing clinical studies of Olverembatinib and Lisaftoclax across multiple hematologic malignancies and treatment settings.

When and where will Ascentage Pharma (AAPG) present data at EHA 2026?

Ascentage Pharma will present data at the EHA 2026 Congress in Stockholm, Sweden, June 11–14, 2026. Key posters are scheduled for Saturday, June 13, 18:45–19:45 CEST, featuring updated efficacy, safety, and correlation analyses for its hematology pipeline.

Which drugs from Ascentage Pharma (AAPG) are featured in the EHA 2026 presentations?

The presentations focus on Olverembatinib (HQP1351) and Lisaftoclax (APG-2575). According to Ascentage Pharma, Olverembatinib is China’s first approved third-generation BCR-ABL inhibitor and Lisaftoclax is the first approved China-developed Bcl-2 selective inhibitor, both still investigational in the US.

Are Ascentage Pharma’s Olverembatinib and Lisaftoclax FDA-approved in the United States?

No, Olverembatinib and Lisaftoclax are not yet FDA-approved in the US. According to Ascentage Pharma, both drugs are currently under investigation, although they hold approvals in China as advanced targeted therapies for hematologic cancers.

What key Olverembatinib data will Ascentage Pharma (AAPG) show at EHA 2026?

Ascentage Pharma will highlight Olverembatinib data in chronic-phase CML, Ph+ ALL, and patients resistant to other TKIs. According to the company, posters include updated efficacy, safety, and combination studies with low-intensity chemotherapy and Lisaftoclax in adult and pediatric populations.

What Lisaftoclax (APG-2575) clinical results is Ascentage Pharma (AAPG) sharing at EHA 2026?

Ascentage Pharma will present a pivotal phase 2 analysis of Lisaftoclax in CLL/SLL, examining correlations between baseline characteristics and prognosis. According to the company, additional data cover combination use with Olverembatinib in pediatric relapsed or refractory Ph+ ALL.

Where can investors find Ascentage Pharma (AAPG) EHA 2026 abstracts and poster details?

Investors can access all Ascentage Pharma EHA 2026 abstracts, including poster and publication-only items, on the official EHA website. According to the company, accepted posters list abstract numbers, authors, and exact presentation times for each featured clinical study.